CAMBRIDGE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) — Prime Medicine, Inc. PRME, a biotechnology company dedicated to providing a new class of differentiated unique curative gene therapies, today announced the completion of its increased public offering of 10,294,118 common shares at a public price of $17.00 per share. The gross proceeds of the offering were approximately US$175.0 million, before deducting underwriting rebates and commissions and other offering costs. In addition, Prime Medicine has granted the underwriters a 30-day option to purchase up to 1,544,117 additional common shares at the IPO price less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on October 20, 2022 under the ticker symbol “PRME”. All shares in the offering were offered by Prime Medicine.
JP Morgan, Goldman Sachs & Co. LLC, Morgan Stanley and Jefferies are acting as joint book-running managers for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 19, 2022. The offer was made only by means of a prospectus. Copies of the definitive prospectus relating to the offering may be obtained from: JP Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by calling (866) 803-9204 or emailing prospectus-eq_fi@jpmchase.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282 by phone: (866) 471-2526 or by email: prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, AT: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by phone at (866) 718-1649 or email Prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by phone at (877) 821-7388 or by…
